Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status

References

1. 1.↵
   1. Chaskis C,
   2. Neyns B,
   3. Michotte A,
   4. et al

   . Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009;72:423–28

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Taal W,
   2. Brandsma D,
   3. de Bruin HG,
   4. et al

   . Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405–10

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Ichihara E,
   2. Kiura K,
   3. Takigawa N,
   4. et al

   . Pseudoprogression of lung cancer after concomitant chemoradiotherapy. Jpn J Clin Oncol 2008;38:140–42

   Abstract/FREE Full Text
4. 4.↵
   1. Chamberlain MC,
   2. Glantz MJ,
   3. Chalmers L,
   4. et al

   . Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82:81–83. Epub 2006 Aug 31

   CrossRefPubMed
5. 5.↵
   1. Chamberlain MC

   . Pseudoprogression in glioblastoma. J Clin Oncol 2008;26:4359, author reply 4359–60

   FREE Full Text
6. 6.↵
   1. Brandes AA,
   2. Tosoni A,
   3. Spagnolli F,
   4. et al

   . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361–67

   Abstract/FREE Full Text
7. 7.↵
   1. Hoefnagels FW,
   2. Lagerwaard FJ,
   3. Sanchez E,
   4. et al

   . Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009;256:878–87

   CrossRefPubMed
8. 8.↵
   1. Sugahara T,
   2. Korogi Y,
   3. Tomiguchi S,
   4. et al

   . Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–09

   Abstract/FREE Full Text
9. 9.↵
   1. Hou BL,
   2. Hu J

   . MRI and MRS of human brain tumors. Methods Mol Biol 2009;520:297–314

   CrossRefPubMed
10. 10.↵
    1. van den Bent MJ,
    2. Vogelbaum MA,
    3. Wen PY,
    4. et al

    . End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009;27:2905–08. Epub 2009 May 18

    FREE Full Text
11. 11.↵
    1. Macdonald DR,
    2. Cascino TL,
    3. Schold SC Jr.,
    4. et al

    . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80

    Abstract
12. 12.↵
    1. Hegi ME,
    2. Diserens AC,
    3. Gorlia T,
    4. et al

    . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Hegi ME,
    2. Liu L,
    3. Herman JG,
    4. et al

    . Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189–99

    Abstract/FREE Full Text
14. 14.↵
    1. Brandes AA,
    2. Franceschi E,
    3. Tosoni A,
    4. et al

    . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192–97

    Abstract/FREE Full Text
15. 15.↵
    1. Brandsma D,
    2. Stalpers L,
    3. Taal W,
    4. et al

    . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453–61

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Palmisano WA,
    2. Divine KK,
    3. Saccomanno G,
    4. et al

    . Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954–58

    Abstract/FREE Full Text
17. 17.↵
    1. Herman JG,
    2. Graff JR,
    3. Myohanen S,
    4. et al

    . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821–26

    Abstract/FREE Full Text
18. 18.↵
    1. Ruben JD,
    2. Dally M,
    3. Bailey M,
    4. et al

    . Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006;65:499–508

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Hu LS,
    2. Baxter LC,
    3. Smith KA,
    4. et al

    . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552–58

    Abstract/FREE Full Text
20. 20.↵
    1. Cha S,
    2. Knopp EA,
    3. Johnson G,
    4. et al

    . Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Cha S,
    2. Lupo JM,
    3. Chen MH,
    4. et al

    . Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078–84

    Abstract/FREE Full Text
22. 22.↵
    1. Chao ST,
    2. Suh JH,
    3. Raja S,
    4. et al

    . The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96:191–97

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Schlemmer HP,
    2. Bachert P,
    3. Henze M,
    4. et al

    . Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002;44:216–22

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Samnick S,
    2. Bader JB,
    3. Hellwig D,
    4. et al

    . Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002;20:396–404

    Abstract/FREE Full Text
25. 25.↵
    1. Tsuyuguchi N,
    2. Sunada I,
    3. Iwai Y,
    4. et al

    . Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056–64

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Tsuyuguchi N,
    2. Takami T,
    3. Sunada I,
    4. et al

    . Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery: in malignant glioma. Ann Nucl Med 2004;18:291–96

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Covarrubias DJ,
    2. Rosen BR,
    3. Lev MH

    . Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004;9:528–37

    Abstract/FREE Full Text